Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lewy Body Parkinson Disease”

381 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 381 results

Post-approval studies (Phase 4)Study completedNCT04489888
What this trial is testing

Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Merck Sharp & Dohme LLC 101
Not applicableWithdrawnNCT05497817
What this trial is testing

Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia

Who this might be right for
Caregiver StressDementiaAlzheimer Dementia+3 more
Mayo Clinic
Not applicableLooking for participantsNCT06439355
What this trial is testing

Single-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis

Who this might be right for
Idiopathic Parkinson's Disease and Lewy Body Disease
Centre Hospitalier Universitaire Dijon 66
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Not applicableStudy completedNCT02572713
What this trial is testing

Systemic Synuclein Sampling Study (S4)

Who this might be right for
Parkinson's Disease
Michael J. Fox Foundation for Parkinson's Research 80
Not applicableStudy completedNCT03030586
What this trial is testing

ADDIA Proof-of-Performance Clinical Study

Who this might be right for
Alzheimer Disease (AD)Frontotemporal Lobar DegenerationDementia with Lewy Bodies (DLB)+3 more
Amoneta Diagnostics SAS 821
Not applicableActive Not RecruitingNCT05779839
What this trial is testing

Caregiver Connections Via Technology in Dementia

Who this might be right for
Caregiver StressDementiaAlzheimer Disease+3 more
Mayo Clinic 355
Large-scale testing (Phase 3)Study completedNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 479
Very early researchLooking for participantsNCT06891703
What this trial is testing

[18F]ACI-15916 PET in α-synucleinopathies

Who this might be right for
Parkinson's Disease (PD)Multiple System Atrophy (MSA)Dementia With Lewy Bodies (DLB)
AC Immune SA 46
Not applicableLooking for participantsNCT04724941
What this trial is testing

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

Who this might be right for
Parkinson Disease
University Hospital Schleswig-Holstein 2,000
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableActive Not RecruitingNCT06389032
What this trial is testing

PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia

Who this might be right for
Lewy Body DementiaParkinson Disease DementiaDementia With Lewy Bodies+1 more
Rush University Medical Center 622
Not applicableLooking for participantsNCT02194816
What this trial is testing

Modifiable Variables in Parkinsonism (MVP)

Who this might be right for
Parkinson's DiseaseParkinsonismMSA - Multiple System Atrophy+6 more
Bastyr University 2,000
Not applicableEnded earlyNCT01602276
What this trial is testing

The Effect of tDCS on Subcortical Brain Functioning

Who this might be right for
Brain Damage, Chronic
Johns Hopkins University 3
Testing effectiveness (Phase 2)Study completedNCT02640729
What this trial is testing

Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

Who this might be right for
Lewy Body DementiaVisual Hallucinations
Axovant Sciences Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT02674061
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Who this might be right for
Ovarian Neoplasms
Merck Sharp & Dohme LLC 376
Not applicableStudy completedNCT02761707
What this trial is testing

Biomarkers in Neural Disorders

Who this might be right for
Parkinson's DiseaseAlzheimer's DiseaseProgressive Supranuclear Palsy+6 more
University of Pennsylvania 54
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130
Large-scale testing (Phase 3)Study completedNCT01905657
What this trial is testing

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 1,034
Testing effectiveness (Phase 2)Looking for participantsNCT05319730
What this trial is testing

Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 230
Load More Results